多西他赛联合顺铂或洛铂腹腔灌注治疗晚期卵巢癌合并腹水疗效比较-论文.pdf

《多西他赛联合顺铂或洛铂腹腔灌注治疗晚期卵巢癌合并腹水疗效比较-论文.pdf》由会员上传分享，免费在线阅读，更多相关内容在行业资料-天天文库。

1、第38卷黑龙江医学Vo1．38，No．62014年第6期HEILONGJIANGMEDICALJOURNALJun．2014633多西他赛联合顺铂或洛铂腹腔灌注治疗晚期卵巢癌合并腹水疗效比较鲁亮，李杭，杨飞月，吴海霞，罗曼，曹辉(贵州省人民医院肿瘤科，贵州贵阳550002)摘要：目的探讨顺铂与洛铂在晚期卵巢癌腹腔化疗中的疗效及副反应。方法我科对2011—01—2012—12间收治的36例晚期卵巢癌术后患者进行回顾性分析，顺铂组16例，洛铂组20例，两组患者腹腔灌注时均予多西他赛全身化疗。结票两组患者CA125值术前与第1次灌注化疗前比较，无统计学差异(P>0．05)

2、。第1次灌注化疗后，顺铂组与洛铂组比较无统计学意义(P>0．05)，而第2次、第3次及第4次化疗后两组的CA125值比较，仍无统计差异(P>0．05)；顺铂组与洛铂组术后有肉眼残留病灶的患者经第1次与第2次化疗后，顺铂组的CA125降到更低水平(P<0．05)；两组在副反应方面(血红蛋白下降、白细胞下降、肝功能损伤及消化道反应方面)顺铂组与洛铂组无统计学差异，肾功能损伤发生率顺铂组高于洛铂组，血小板下降发生率顺铂组低于洛铂组。结论晚期卵巢癌患者经过肿瘤细胞减灭术后合并腹水，予顺铂或洛铂行腹腔灌注化疗，并结合多西他赛全身化疗，均有效可行，而对有肉眼残留病灶的患者，予顺

3、铂腹腔灌注化疗可能在比较短的疗程内见效。关键词：顺铂；洛铂；卵巢癌；腹腔灌注；多西他赛doi：10．3969／j．issn．1004—5775．2014．06．009学科分类代码：320．67中图分类号：R737．31文献标识码：BComparisonofCisplatinandLobaplatininIntraperitonealPerfusionChemotherapyforAdvancedOvarianCancerwithAscites／LULiang，LIHang，YANGFei—yue，eta1．／／(OncologyDepartment，GuizhouP

4、rovincePeopleSHospital，Guiyang550002，CHINA)Abstract：0bjectiveToevaluateefficacyandtoxicityofcisplatinandlobaplatininintraperitonealperfusionchemotherapyforad-vancedovariancancerwithascites．MethodsRetrospectiveanalysiswasusedtoanalyzetheclinicalmaterialsof36casesaboutpostopera—tiveadvan

5、cedovariancancerinOncologyDepartmentofthePeopleSHospital，ProvinceGuizhoufromJanuary2011toDecember2012，with16casesincisplatingroup(Agroup)and20casesinlobaplatingroup(Bgroup)．Docetaxelchemotherapywasusedonallthepatientsduringintraperitonealperfusion．ResultsThereWasnosignificantdiferencei

6、nCA125betweenAgroupandBgroupinfirstpreandpostchemotherapy(P>0．05)．Therewasnostatisticalsignificancebetweentwogroupsafterthesecond，thirdandfourthcyclechemotherapy(P>0．05)．Butforthepatientswithgrossresidualdisease，afterthefirstorsecondcyclechemotherapy，CA125levelsinAgroupwerelowerthantha

7、tinBgroup(P<0．05)．Therewerenostatisticalsignificancebetweentwogroupsinthetoxicitiesofhemoglobin，lowerwhitebloodcell，digestivedisturbanceandliverfunctiondamage；butAgroupwerehigherthanthatinBgroupinplateletdecreaseandrenalfunctiondamage．ConclusionIntraperitonealpefusionchemotherapywith